Pricing

VIVO CAPITAL, LLC

2 followers ·
PALO ALTO CA Investment Advisor Hedge Fund
13F Summary

Subscription Required

Equal-WT
WhaleScore 2.0 ?

85

S&P 500
WhaleScore ?

Subscription Required

Equal-WT
WhaleScore 1.0 ?

Vivo Capital is based out of Palo Alto. Their last reported 13F filing for Q4 2023 included $1,221,329,711 in managed 13F securities and a top 10 holdings concentration of 72.94%. Vivo Capital's largest holding is Soleno Therapeutics Inc with shares held of 8,418,093. Whalewisdom has at least 35 13F filings, and 3 13D filings

2023-12-31

Top Buys (13F)

Name % Change
SLNO Soleno Therapeutics 17.39%
TRML Tourmaline Bio Inc 1.27%
SLN Silence Therapeutics 0.73%
PHVS Pharvaris BV 0.65%
ENGN enGene Holdings Inc 0.51%

2023-12-31

Top Sells (13F)

Name % Change
SVA Sinovac Biotech Ltd 4.18%
ACLX Arcellx Inc 1.98%
VTYX Ventyx Biosciences I 1.61%
TARS Tarsus Pharmaceutica 1.45%
RYZB RayzeBio Inc. 0.98%

2023-12-31

13F Holdings Summary

Name $ Change
SLNO Soleno Therapeutics 27.74%
GRCL Gracell Biotechnolog 7.85%
VRNA Verona Pharma PLC AD 6.92%
HRMY Harmony Biosciences 6.89%
ALXO ALX Oncology Holding 5.14%

2023-12-31

13F Activity

Market Value $1.22b, Prior: $0.91b
New Purchases 4 stocks
Added To 8 stocks
Sold out of 10 stocks
Reduced holdings in 8 stocks
Top 10 Holdings % 72.94%
Turnover %[1] 29.79%
Turnover Alt %[2] 9.44%
Time Held Top 20 4.2 quarters
Time Held Top 10 4.4 quarters
Time Held All 9.15 quarters

[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.

[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2023-12-31

13F Sector Allocation Over Time

2023-12-31

Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2023-12-31

Portfolio Performance